Who should control access to AHSCT as a treatment for MS? The patient, the healthcare provider or the healthcare system? Have your say!
A Saturday morning doodle what do you think?I am trying to create a logo for the MS-Selfie Newsletter. This is my first attempt what do you think? Does the self-help philosophy behind what…
A case of rapidly progressing secondary progressive MS despite treatment with rituximab. How to investigate and manage SPMS and at the same time managi…
Having some idea of how bad your MS is, or not, will allow you to discuss with your neurologist issues around what level of treatment is appropriate fo…
A patient with rapidly-evolving severe MS is having doubts about the decision to be treated with cladribine. Should she abort the cladribine and have A…
Why is death and dying such a taboo for MS stakeholders and society in general? Have you completed an advanced directive or living will?
A colleague suggested to me that the whole academic neurology community has imbibed too much anti-CD20 Kool-Aid and it is time for us to sober up. Is s…
This patient wants to switch from an anti-CD20 therapy to oral cladribine in the hope that it is going to allow him to make an antibody response to the…
See all